{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.7","upperLimit":"71.9","value":"52.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"NUMBER","populationDescription":"Patients who had a good complete remission (CR), CR with evidence of minimal residual disease (MRD), or complete remission with incomplete blood count recovery (CRi) following treatment. Cheson AML Response Criteria are used to assess response.Good CR is defined as \\<5% blasts in marrow, no MRD and recovery of blood counts by day 35 after induction.","reportingStatus":"POSTED","timeFrame":"1 year after treatment with IAP","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of patients with PFS"}